Numerical methods for decision-making in clinical care: where to now? Sir, I found this editorial (March 1988 JRSM, p 128) both interesting and instructive. I have the feeling that Dr Young is living a long way from the cutting edge of modern management budgeting. While our DHA Directorate is ankle deep in computers costing thousands of pounds, I have only just managed to scrounge a secondhand computer surplus to the requirements of our finance department. This, at least, will allow us to put some of our more routine waiting lists onto disc, but it has been largely a matter of luck.
The clinical staff have not been encouraged to use computers in their work, and the computers themselves have always been taken from the medical equipment budget. Since it has always been a matter of balancing computers against hard equipment such as replacement monitors, there has been no possibility of supplying ourselves with these aids for diagnosis 
Simplifying infusion chemotherapy
Sir, The object of breast cancer chemotherapy is to make as many patients as possible as well as possible for as long as possible. The preliminary communication by Ebbs et al: (January 1988 JRSM, p 13) raises worrying therapeutic and ethical questions. The use of single drugs in patients with advanced breast cancer is questionable because combination chemotherapy produces higher response rates and a greater chance of significant prolongation of good quality life 1 ,2,3 Having reduced their patients' prognoses by choosing to use single drugs, the King's Group refuse to use what they admit is the most effective single agent, i.e. adriamycin which, they say, is 'extremely toxic'. This statement is scientifically meaningless. The side effects of any drug are not only a function of the chemical properties of the compound as such but also of the way in which it is given. It is illogical to make sweeping generalizations about the side effects of drugs without stating how they were given and what steps were taken to minimize such effects. For example, the side effects of most combination cancer chemotherapy programmes, including those with adriamycin, can be significantly reduced by admitting the patients to hospital, giving them high doses of combined antiemetics as a premedication and administering the drugs in full doses over 24 h instead of over several days. Approximately 80% of patients treated in this way will have no vomiting or diarrhoea, only rarely experience nausea, and lead a virtually normal life between treatment cycles. Apart from temporary alopecia there is not a single side effect of adriamycin which cannot be avoided by giving the drug by this method and observing a few simple and well known precautions. The validity of this approach has been extensively tested over the last 15 years 4 -6 and confirmed by several different groups7,8
This raises the question of whether these patients are being informed that they are not being given the currently best available treatment. If they are not so informed, this poses a serious ethical dilemma: either the King's Group are unaware of facts which it is their duty to know or they are giving suboptimal treatment to uninformed patients. Either way, in my opinion, the study is unethical. Failure to realize that anticancer drugs can now be given much more safely and with far fewer side effects than in the past is wrong for two reasons: (1), many patients receiving chemotherapy are sutTering from side effects which could largely be prevented, and (2), the constant emphasis on only the negative aspects of the drug treatment of breast cancer means that many patients with advanced disease are being deprived of the benefits of optimum chemotherapy as are those with 'high risk' tumours at the time of diagnosis, many of whom are being given adjuvant tamoxifen alone instead of tamoxifen plus combination chemotherapy. This situation will never improve unless we base our treatment on current evidence and unless we abandon the assumption that we alone are concerned about the quality of life of patients receiving chemotherapy. Whatever differing views there may be in the medical profession about the treatment of breast cancer all patients are entitled to be fully informed, objectively of all the available treatment options. L A PRICE Sir, We agree with Dr Price that the intention of treating advanced breast cancer should be to preserve quality and quantity of life, but why does he argue that combination chemotherapy is to be preferred simply because it may produce higher response rates? Selective referencing from articles largely over 10 years old, may produce evidence to support such a conception, but there is, in fact, little evidence from randomized studies that combination therapy does produce higher response rates than single agent, adriamycinl. There is also very little evidence from Dr Price's former colleagues that the improvement of response rates obtained by using chemotherapy substantially prolongs life 2 • Is Dr Price correct in arguing that we should have used adriamycin? Again we would answer no. All published randomized studies that we are aware of indicate that epirubicin produces at least equal response rates but with less toxicity to adriamycin whether used as single agent or in combinationv'. Our choice of a weekly regimen is also appropriate because this approach seems to offer preservation of objective response, but with diminution of side effects", We agree with the statement that mode of delivery alters the side effects of drugs: Dr Price appears not to grasp that was the whole point of our study. Previous studies have indicated anthracycline infusions to be as effective as bolus doses when both have been used every 3 weeks again with reduced toxicity", It therefore appeared logical to investigate the use of weekly infusion epirubicin and by doing so we have avoided the almost universal alopecia, that is often only 'temporary' until death intervenes. Dr Price considers this side effect unimportant: we remain unconvinced his patients would agree.
Working within the strict financial limitations of the NHS we are keen to avoid repeated and costly admissions for infusion therapy and have managed successfully to treat patients in this way as outpatients largely without the need for any antiemetics. The issue of the value of the addition of chemotherapy to tamoxifen as adjuvant treatment for early breast cancer is irrelevant to our preliminary communication on advanced breast cancer chemotherapy. We have corresponded with Dr Price on this subject elsewhere questioning the ethics of advocating adjuvant polychemotherapy for postmenopausal women'-". We think that our recommendations are ethical as they are supported by the majority in this country. We accept that Dr Price may rationally hold different opinions. Recent evidence from America now suggests that thromboembolic complications may be added to the hazards of adjuvant chemotherapy". In fact, American opinion now appears to be against the use of adjuvant chemotherapy in postmenopausal women'". Where does this leave Dr Price? We trust he will also be interested in the overview on this topic, due to be published shortly, which fails to corroborate his views!'. We wish for no monopoly on caring about patients quality of life, and we hope that Dr Price is concerned sufficiently to be documenting the subjective changes his intensive treatments produce. S R EBBS M BAUM
